Does one size fit all? Risks and benefits of neoadjuvant chemoradiation in patients with clinical stage IIA rectal cancer requiring abdominoperineal resection

MLA

David W. Dietz, et al. “Does One Size Fit All? Risks and Benefits of Neoadjuvant Chemoradiation in Patients with Clinical Stage IIA Rectal Cancer Requiring Abdominoperineal Resection.” The American Journal of Surgery, vol. 219, Mar. 2020, pp. 406–10. EBSCOhost, https://doi.org/10.1016/j.amjsurg.2019.10.037.

APA

David W. Dietz, Conor P. Delaney, Emre Gorgun, Xhileta Xhaja, Michael A. Valente, Matthew F. Kalady, David Liska, Alexandra Aiello, Scott R. Steele, & Mariane Gouvea Monteiro de Camargo. (2020). Does one size fit all? Risks and benefits of neoadjuvant chemoradiation in patients with clinical stage IIA rectal cancer requiring abdominoperineal resection. The American Journal of Surgery, 219, 406–410. https://doi.org/10.1016/j.amjsurg.2019.10.037

Chicago

David W. Dietz, Conor P. Delaney, Emre Gorgun, Xhileta Xhaja, Michael A. Valente, Matthew F. Kalady, David Liska, Alexandra Aiello, Scott R. Steele, and Mariane Gouvea Monteiro de Camargo. 2020. “Does One Size Fit All? Risks and Benefits of Neoadjuvant Chemoradiation in Patients with Clinical Stage IIA Rectal Cancer Requiring Abdominoperineal Resection.” The American Journal of Surgery 219 (March): 406–10. doi:10.1016/j.amjsurg.2019.10.037.